作者
Ugur Sahin, Petra Oehm, Evelyna Derhovanessian, Robert A Jabulowsky, Mathias Vormehr, Maike Gold, Daniel Maurus, Doreen Schwarck-Kokarakis, Andreas N Kuhn, Tana Omokoko, Lena M Kranz, Mustafa Diken, Sebastian Kreiter, Heinrich Haas, Sebastian Attig, Richard Rae, Katarina Cuk, Alexandra Kemmer-Brück, Andrea Breitkreuz, Claudia Tolliver, Janina Caspar, Juliane Quinkhardt, Lisa Hebich, Malte Stein, Alexander Hohberger, Isabel Vogler, Inga Liebig, Stephanie Renken, Julian Sikorski, Melanie Leierer, Verena Müller, Heidrun Mitzel-Rink, Matthias Miederer, Christoph Huber, Stephan Grabbe, Jochen Utikal, Andreas Pinter, Roland Kaufmann, Jessica C Hassel, Carmen Loquai, Özlem Türeci
发表日期
2020/9/3
期刊
Nature
卷号
585
期号
7823
页码范围
107-112
出版商
Nature Publishing Group UK
简介
Treating patients who have cancer with vaccines that stimulate a targeted immune response is conceptually appealing, but cancer vaccine trials have not been successful in late-stage patients with treatment-refractory tumours,. We are testing melanoma FixVac (BNT111)—an intravenously administered liposomal RNA (RNA-LPX) vaccine, which targets four non-mutated, tumour-associated antigens that are prevalent in melanoma—in an ongoing, first-in-human, dose-escalation phase I trial in patients with advanced melanoma (Lipo-MERIT trial, ClinicalTrials.gov identifier NCT02410733). We report here data from an exploratory interim analysis that show that melanoma FixVac, alone or in combination with blockade of the checkpoint inhibitor PD1, mediates durable objective responses in checkpoint-inhibitor (CPI)-experienced patients with unresectable melanoma. Clinical responses are accompanied by the …
学术搜索中的文章
U Sahin, P Oehm, E Derhovanessian, RA Jabulowsky… - Nature, 2020